Skip to main content
GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observe

Dr. John Cush RheumNow

7 months ago
GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase 3 trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://t.co/xIC7Vqx659 https://t.co/6n3XfXeeg2
Best of 2025: Dermatomyositis Reviewed

Researchers from the University of Pennsylvania have published an open-access r

Dr. John Cush RheumNow

7 months ago
Best of 2025: Dermatomyositis Reviewed Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options. https://t.co/0vDvqIcj6U https://t.co/ogPjPI5gJa
APP Pearls “Get to know your patients and any barriers they have that may impact their healthcare” - Natalie Lane, F

Dr. John Cush RheumNow

7 months ago
APP Pearls “Get to know your patients and any barriers they have that may impact their healthcare” - Natalie Lane, FNP-C
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed i

Dr. John Cush RheumNow

7 months ago
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns https://t.co/uVKuhhc80F https://t.co/9EhyBpSaAE
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, Sout

Dr. John Cush RheumNow

7 months ago
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/Yg7DBOTW8o
JAMA -- Full read review "Uveitis in Adults:"
- affects adults 20 to 50 years
- noninfectious anterior uveitis: cortico

Dr. John Cush RheumNow

7 months ago
JAMA -- Full read review "Uveitis in Adults:" - affects adults 20 to 50 years - noninfectious anterior uveitis: corticosteroids 1st line Rx - posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line https://t.co/BJQkPtK2z2 https://t.co/0puqX5iieE
Best of 2025: Vitamin D for Prevention of Disease

JAMA has published a clinical guideline on the use of vitamin D to p

Dr. John Cush RheumNow

7 months ago
Best of 2025: Vitamin D for Prevention of Disease JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults. https://t.co/PFHO7x5nxH https://t.co/fvwzLgYGJe
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatolog

Dr. John Cush RheumNow

7 months ago
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatology condition that they have” - Lindsay Tom, PA-C
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?

Recent large-scale clinical trials have broade

Dr. John Cush RheumNow

7 months ago
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology? Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions. https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy.
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest res

Dr. John Cush RheumNow

7 months ago
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based
2025 ACR Guideline for the Treatment of SLE

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment

Dr. John Cush RheumNow

7 months ago
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/S7Cwzbgnde
×